User contributions for Edzelco

Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

8 May 2024

20 April 2024

18 April 2024

17 April 2024

16 April 2024

  • 05:5005:50, 16 April 2024 diff hist +18 User:Edzelco→‎Pages Authored/Co-authored/Collaborated
  • 05:5005:50, 16 April 2024 diff hist +34,175 N CapivasertibCreated page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based..." current
  • 05:2805:28, 16 April 2024 diff hist +15 User:Edzelco→‎Pages Authored/Co-authored/Collaborated
  • 05:2705:27, 16 April 2024 diff hist +33,311 N IptacopanCreated page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me..." current

15 April 2024

24 March 2024

18 February 2024

16 February 2024

11 February 2024

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)